Labeling of diphenhydramine-containing drug products for over-the-counter human use. Final rule.
The Food and Drug Administration (FDA) is issuing a final rule amending the final monographs for over-the-counter (OTC) antiemetic, antihistamine, antitussive, and nighttime sleep-aid drug products to add a warning statement for oral products containing diphenhydramine citrate or diphenhydramine hydrochloride. The warning advises consumers not to use oral OTC diphenhydramine products with any other product containing diphenhydramine, including products used topically. This final rule also includes the agency's conclusions on additional warning statements and a direction statement for OTC external analgesic drug products containing diphenhydramine hydrochloride. These conclusions will be incorporated into the final monograph for OTC external analgesic drug products in a future issue of the Federal Register. FDA is issuing this final rule after considering public comments on the agency's proposed regulation and all new data and information on drug products containing diphenhydramine that have come to the agency's attention
D000287:Administration, Topical; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D000996:Antitussive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D002644:Chickenpox / Q000188:drug therapy; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence; D011040:Dermatitis, Toxicodendron / Q000188:drug therapy; D004155:Diphenhydramine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D008457:Measles / Q000188:drug therapy; D004366:Nonprescription Drugs / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D013471:Sunburn / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D000700:Analgesics; D000932:Antiemetics; D000996:Antitussive Agents; D006634:Histamine H1 Antagonists; D006993:Hypnotics and Sedatives; D004366:Nonprescription Drugs; D004155:Diphenhydramine